Open AccessMometasone furoate effect on interleukin-6 of adenoid surface and serum in adenoid hypertrophy patients
Author(s) -
Zainul Mujahid,
Rus Suheryanto,
Iriana Maharani
Publication year - 2021
Publication title -
oto rhino laryngologica indonesiana/oto-rhino-laryngologica indonesiana
Language(s) - English
Resource type - Journals
eISSN - 0216-3667
pISSN - 2598-3970
DOI - 10.32637/orli.v51i1.362
Subject(s) - adenoid hypertrophy , nasal administration , adenoid , medicine , mometasone furoate , gastroenterology , immunology , pathology , corticosteroid , adenoidectomy , tonsillectomy
Background: Adenoid hypertrophy is one of the most common problems in children resulting in obstruction of the posterior nasal. Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a role in acute and chronic infections, hematopoesis, T cells and B cells formation. Purpose: To determine the effect of intranasal mometasone furoate administration on IL-6 level of adenoid surface and serum and the adenoid size in patients with adenoid hypertrophy. Method: A one group pre- and posttest design involving 17 patients age 5 to 14 years. The patients underwent nasoendoscopic examination to determine the adenoid size, measurement of adenoid surface IL-6, and serum IL-6 level before and after 6 weeks treatment of intranasal mometasone furoate. Results: There were significant decrease of the adenoid surface IL-6 level, serum IL-6 level, and adenoid size with a p value <0.05. There was a significant positive correlation between the levels of adenoid surface IL-6 and serum IL-6 (r=0.517; p=0.033). A significant positive correlation was obtained between the decrease of adenoid surface and serum IL-6 levels with the decrease of adenoid size (p<0.05). Conclusion: The use of intranasal mometasone furoate can decrease the IL-6 levels of adenoid surface and serum, and the adenoid size in patients with adenoid hypertrophy.